Literature DB >> 33386981

Vessel-selective 4D MRA based on ASL might potentially show better performance than 3D TOF MRA for treatment evaluation in patients with intra-extracranial bypass surgery: a prospective study.

Maoxue Wang1, Yongbo Yang2, Yi Wang2, Ming Li1, Jilei Zhang3, Bing Zhang4,5.   

Abstract

OBJECTIVES: To compare bypass patency and intracranial collaterals from the external carotid artery (ECA) by four-dimensional MR angiography (MRA) based on super-selective pseudo-continuous arterial spin labeling (pCASL) combined with the keyhole and view-sharing techniques (4D-sPACK) versus three-dimensional time-of-flight (3D TOF) MRA in patients with extra-intracranial revascularization.
METHODS: The MR data of 45 patients administered bypass surgery were collected. The image quality of 4D-sPACK was evaluated using a 4-point grading system according to whether the diagnosis of intracranial collaterals was affected. Anastomosis patency and intracranial collateral visualization from ECA were assessed by two radiologists on 4D-sPACK and 3D TOF MRA, with digital subtraction angiography (DSA) findings as reference. Intracranial collateral assessment employed another 4-point grading system according to the number of vessels shown. Interobserver agreement was assessed with the weighted kappa statistic.
RESULTS: Fifty hemispheres in 43 patients were included. The image quality of 4D-sPACK was good in 47 (47/50, 94.0%) hemispheres. 4D-sPACK had a higher sensitivity than 3D TOF MRA (97.73% vs 79.55%) for visualizing anastomoses. There were significant differences between 4D-sPACK (scores, 3.22 ± 1.15) and 3D TOF MRA (scores, 1.80 ± 0.67) in the visualization of intracranial collaterals from ECA (p < 0.001). The interobserver agreement was substantial for intracranial collateral assessment (κ4D-sPACK = 0.788; κ3D TOF MRA = 0.800) and almost perfect for bypass patency (κ4D-sPACK = 0.912; κ3D TOF MRA = 0.816; κDSA = 0.811).
CONCLUSION: This pilot study shows that, 4D-sPACK has a better performance than 3D TOF MRA in treatment evaluation of patients after bypass surgery, and has high consistency with DSA. KEY POINTS: • 4D-sPACK is a non-contrast-enhanced dynamic MRA method for the visualization of intracranial vessels. • 4D-sPACK has higher specificity for the diagnosis of anastomosis occlusion. • 4D-sPACK is better than 3D TOF MRA in the visualization of intracranial collaterals in patients after bypass surgery.

Entities:  

Keywords:  Arterial spin labeling; Cerebral revascularization; Digital subtraction angiography; Magnetic resonance angiography

Year:  2021        PMID: 33386981     DOI: 10.1007/s00330-020-07503-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  1 in total

1.  Comparison of CBF Measured with Combined Velocity-Selective Arterial Spin-Labeling and Pulsed Arterial Spin-Labeling to Blood Flow Patterns Assessed by Conventional Angiography in Pediatric Moyamoya.

Authors:  D S Bolar; B Gagoski; D B Orbach; E Smith; E Adalsteinsson; B R Rosen; P E Grant; R L Robertson
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-06       Impact factor: 3.825

  1 in total
  3 in total

1.  Acceleration of pCASL-Based Cerebral 4D MR Angiography Using Compressed SENSE: A Comparison With SENSE.

Authors:  Maoxue Wang; Yiming Ma; Fei Chen; Fei Zhou; Jilei Zhang; Bing Zhang
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

2.  High-resolution compressed sensing time-of-flight MR angiography outperforms CT angiography for evaluating patients with Moyamoya disease after surgical revascularization.

Authors:  Shujing Ren; Wei Wu; Chunqiu Su; Qianmiao Zhu; Michaela Schmidt; Yi Sun; Christoph Forman; Peter Speier; Xunning Hong; Shanshan Lu
Journal:  BMC Med Imaging       Date:  2022-04-07       Impact factor: 1.930

3.  Preoperative Collateral Perfusion Using Arterial Spin Labeling: A Predictor of Surgical Collaterals in Moyamoya Angiopathy.

Authors:  Maoxue Wang; Yi Wang; Wen Zhang; Xiance Zhao; Yongbo Yang; Bing Zhang
Journal:  Front Neurosci       Date:  2022-03-14       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.